Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
Virtus KAR Health Sciences Inst HLHIX Fund Analysis
Morningstar’s Analysis HLHIX
Will HLHIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar